Skip to search formSkip to main contentSkip to account menu

JM 216

Known as: JM-126, JM-216, JM216 
National Institutes of Health

Related topics

Related topics

2 relations
BMS-182751

Broader (1)

satraplatin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2004
Highly Cited
2004
A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration
JM216 [bis-acetato-ammine-dichloro-cyclohexylamine-platinum (IV)] is an oral platinum complex with in vivo activity against… 
2004
2004
A Phase I Trial of the Oral Platinum Analogue JM216 with Concomitant Radiotherapy in Advanced Malignancies of the Chest
JM216 is an orally administered platinumanalogue. We undertook this study todetermine the maximally tolerated dose(MTD) of JM216… 
2002
2002
A phase II trial of JM-216 in cervical cancer: an NCIC CTG study.
OBJECTIVE BMS-182751 (JM-216) is an orally bioavailable platinum compound with activity in platinum-sensitive and platinum… 
2000
2000
Combined effects of the orally active cisplatin analog, JM216, and radiation in antitumor therapy
Purpose: We evaluated the orally administered platinum agent, JM216, in combination with ionizing radiation both in vivo and in… 
2000
2000
Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients
Purpose: The purpose of this study was to assess renal function in patients treated with the oral platinum drug JM216 [bisacetato… 
1999
1999
Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer.
PURPOSE This multicenter phase II trial was performed to determine tumor efficacy and tolerance of the oral platinum drug JM216… 
1998
1998
Phase I study of oral JM216 given twice daily
Abstract JM216 [bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV)] is an oral platinum complex that is currently in phase… 
Highly Cited
1997
Highly Cited
1997
Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer.
PURPOSE We aimed to determine the maximum-tolerated dose (MTD) clinical toxicities, pharmacokinetics, and pharmacodynamics of… 
1997
1997
Combination chemotherapy involving orally administered etoposide and JM-216 in murine tumor models
Purpose: Orally administered VP-16 (etoposide) was evaluated in combination with an orally administered platinum analog, JM-216… 
1996
1996
Studies on the Oral Anticancer Drug JM-216: Synthesis and Characterization of Isomers and Related Complexes.
The complex cis,trans,cis-[PtCl(2)(OAc)(2)NH(3)(c-C(6)H(11)NH(2))] (JM-216) is currently undergoing clinical evaluation as an… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)